EcoDrugPlus

Adenosine Receptor A1-Like

Ensembl ID : ENSSTUG00000038037
Gene Symbol: LOC115168665
3 Cross references
149 Possible Orthologues:

Adenosine Receptor A2a-Like

Ensembl ID : ENSSTUG00000007548
Gene Symbol: LOC115199962
3 Cross references
184 Possible Orthologues:

Adenosine Receptor A2b-Like

Ensembl ID : ENSSTUG00000014986
Gene Symbol: LOC115148855
3 Cross references
192 Possible Orthologues:

Adenosine Receptor A2b-Like

Ensembl ID : ENSSTUG00000011703
Gene Symbol: LOC115155094
3 Cross references
191 Possible Orthologues:

Adenosine Receptor A3-Like

Ensembl ID : ENSSTUG00000016360
Gene Symbol: LOC115207415
2 Cross references
134 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSSTUG00000011029
Gene Symbol: ADRA1B
3 Cross references
190 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSSTUG00000036211
Gene Symbol: ADRA1B
3 Cross references
190 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSSTUG00000032241
Gene Symbol: ADRA1B
3 Cross references
185 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSSTUG00000046685
Gene Symbol: ADRA1D
3 Cross references
188 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSSTUG00000016236
Gene Symbol: ADRA1D
3 Cross references
187 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSSTUG00000017289
Gene Symbol: ADRA2A
3 Cross references
153 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSSTUG00000038577
Gene Symbol: ADRA2A
1 Cross references
153 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).